Cargando…
Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, dos...
Autores principales: | Perroud, Herman Andrés, Scharovsky, O Graciela, Rozados, Viviana Rosa, Alasino, Carlos María |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336390/ https://www.ncbi.nlm.nih.gov/pubmed/28275392 http://dx.doi.org/10.3332/ecancer.2017.723 |
Ejemplares similares
-
Metronomic chemotherapy: changing the paradigm that more is better
por: Scharovsky, O.G., et al.
Publicado: (2009) -
Highlights from the 1st Latin American meeting on metronomic chemotherapy and drug repositioning in oncology, 27–28 May, 2016, Rosario, Argentina
por: Rosé, Adriana, et al.
Publicado: (2016) -
Losartan improves the therapeutic effect of metronomic cyclophosphamide in triple negative mammary cancer models
por: Mainetti, Leandro E., et al.
Publicado: (2020) -
Metronomic chemotherapy using oral cyclophosphamide and bevacizumab for recurrent cervical cancer: A multi-institutional retrospective study
por: Isono-Taniguchi, Roze, et al.
Publicado: (2022) -
Metronomic chemotherapy
por: Maiti, Rituparna
Publicado: (2014)